Evidence map›Paper›PMID 36013249›Full record

ArticleJournal of personalized medicine2022

First Two-Year Observational Exploratory Real Life Clinical Phenotyping, and Societal Impact Study of Parkinson's Disease in Emiratis and Expatriate Population of United Arab Emirates 2019-2021: The EmPark Study.

Vinod Metta, Huzaifa Ibrahim, Tom Loney, Hani T S Benamer, Ali Alhawai, Dananir Almuhairi, Abdulla Al Shamsi, Sneha Mohan, Kislyn Rodriguez, Judith Mohan and 11 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Absence of theFrontiers in aging neuroscience · 2025
    Article
  8. Observational
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 5 countries.

Vinod MettaPsychology & Neuroscience, Department of Neurosciences, Institute of Psychiatry, King's College London, London, UK.ORCID 0000-0002-8970-8595
Huzaifa IbrahimParkinson's Association, Dubai, United Arab Emirates.
Tom LoneyCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.ORCID 0000-0003-1687-6587
Hani T S BenamerCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.
Ali AlhawaiHigher Colleges of Technology, Dubai, United Arab Emirates.
Dananir AlmuhairiParkinson's Association, Dubai, United Arab Emirates.
Abdulla Al ShamsiParkinson's Association, Dubai, United Arab Emirates.
Sneha MohanKings College Hospital London, Dubai, United Arab Emirates.
Kislyn RodriguezKings College Hospital London, Dubai, United Arab Emirates.
Judith MohanKings College Hospital London, Dubai, United Arab Emirates.
Margaret O'SullivanKings College Hospital London, Dubai, United Arab Emirates.
Neha MuralidharanKings College Hospital London, Dubai, United Arab Emirates.
Sheikha Al MazrooeiStem Cell Association, Dubai, United Arab Emirates.
Khadeeja Dar MousaDubai Statistics Centre, Dubai, United Arab Emirates.
Guy Chung-FayePsychology & Neuroscience, Department of Neurosciences, Institute of Psychiatry, King's College London, London, UK.
Rukmini MrudulaNizams Institute of Medical Sciences, Hyderabad, Telangana, India.
Cristian Falup-PecurariuDepartment of Neurology, Transilvania University of Brasov, Brasov, Romania.
Carmen Rodriguez BilazquezInstitute of Salud Carlos 111, Madrid, Spain.ORCID 0000-0003-3829-0675
Maryam MatarGenetic Disease Association, Dubai, United Arab Emirates.
Rupam BorgohainNizams Institute of Medical Sciences, Hyderabad, Telangana, India.
K Ray ChaudhuriPsychology & Neuroscience, Department of Neurosciences, Institute of Psychiatry, King's College London, London, UK.ORCID 0000-0003-2815-0505
Dubai Hospital · AEKing's College London · GBMohammed Bin Rashid University of Medicine and Health Sciences · AENizam's Institute of Medical Sciences · INHigher Colleges of Technology · AEInstituto de Salud Carlos III · ESTransylvania University of Brașov · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPhenotypic differences in Parkinson's Disease (PD) among locals (Emiratis) and Expatriates (Expats) living in United Arab Emirates have not been described and could be important to unravel local aspects of clinical heterogenicity of PD pointing towards genetic and epigenetic variations.

objectiveTo investigate the range and nature of motor and nonmotor clinical presentations of PD and its impact on time to diagnosis, local service provisions, and quality of life in Emiratis and Expats in UAE, as well as address the presence of current unmet needs on relation to care and etiopathogenesis of PD related to possible genetic and epigenetic factors.

methodsa cross-sectional one point in time prospective, observational real-life study of 171 patients recruited from PD and Neurology clinics across United Arab Emirates from 2019-2021. Primary outcomes were sociodemographic data, motor and nonmotor symptoms (NMS), including cognition and sleep, and quality of life (QOL) assessments, Results: A total of 171 PD patients (52 Emiratis 119 Expats) were included with mean age (Emiratis 48.5 (13.1) Expats 64.15 (13.1)) and mean disease duration (Emiratis 4.8 (3.2) Expats 6.1 (2.9)). In the Emiratis, there was a significant mean delay in initiating treatment after diagnosis (Emiratis 1.2 (0.9) Expats 1.6 (1.1)), while from a clinical phenotyping aspect, there is a high percentage of akinesia 25 (48.1) or tremor dominant (22 (42.3)) phenotypes as opposed to mixed subtype 67 (56.3) in Expat cohorts; double tremor dominant, especially Emirati females (25%), had a predominant lower limb onset PD. Both Emirati (27.9 (24.0)) and Expat 29.4 (15.6) showed moderate NMS burden and the NMS profile is dominated by Sleep, Fatigue, Mood, Emotional well-being 3.0 (1.1) and Social Stigma 3.5 (0.9) aspects of PDQ8 SI measurements are predicted worse QOL in Emiratis, while lack of social support 2.3 (1.3) impaired QOL in Expat population. Awareness for advanced therapies was low and only 25% of Emiratis were aware of deep brain surgery (DBS), compared to 69% Expats. Only 2% of Emiratis, compared to 32% of Expats, heard of Apomorphine infusion (CSAI), and no (0%) Emiratis were aware of intrajejunal levodopa infusion (IJLI), compared to 13% of expats.

conclusionOur pilot data suggest clinical phenotypic differences in presentation of PD in Emiratis population of UAE compared to expats. Worryingly, the data also show delayed treatment initiation, as well as widespread lack of knowledge of advanced therapies in the Emirati population.

Indexed as

device aided therapiesEmiratisepigeneticsexpatriategeneticnon motor symptomsquality of lifesocietal impactyoung onset Parkinson’s (YOPD)

Identifiers

PMID36013249
PMCPMC9410099
OpenAlexW4291017286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.